MRI of rectal cancer: An overview and update on recent advances

American Journal of Roentgenology

Volumn 205, Issue 1, 2015, Pages W42-W55

  Jhaveri, Kartik S ^a   Hosseini Nik, Hooman ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Chemoradiation therapy; MRI; Rectal cancer; Recurrence; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; FERUMOXYTOL; GADOFOSVESET; GADOLINIUM; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; CONTRAST MEDIUM;

ADJUVANT CHEMORADIOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; EXTRAMURAL VASCULAR INVASION; HUMAN; IMAGE QUALITY; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECTUM CANCER; RECTUM SURGERY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR RECURRENCE; CHEMORADIOTHERAPY; PATHOLOGY; PROCEDURES; RECTAL NEOPLASMS;

CHEMORADIOTHERAPY; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECTAL NEOPLASMS;

EID: 84938522197     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.14.14201     Document Type: Review

References (95)

1. Kang H, O'Connell JB, Leonardi MJ, Maggard MA, McGory ML, Ko CY. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis 2007; 22:183-189
2. Adam IJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994; 344:707-711
3. Kelly SB, Mills SJ, Bradburn DM, Ratcliffe AA, Borowski DW; Northern Region Colorectal Cancer Audit Group. Effect of the circumferential resection margin on survival following rectal cancer surgery. Br J Surg 2011; 98:573-581
4. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998; 133:894-899
5. Kosinski L, Habr-Gama A, Ludwig K, Perez R. Shifting concepts in rectal cancer management: a review of contemporary primary rectal cancer treatment strategies. CA Cancer J Clin 2012; 62:173-202
6. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a metaanalysis. Radiology 2004; 232:773-783
7. Beets-Tan RG, Lambregts DM, Maas M, et al. Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2013; 23:2522-2531
8. Fernandez-Esparrach G, Ayuso-Colella JR, Sendino O, et al. EUS and magnetic resonance imaging in the staging of rectal cancer: a prospective and comparative study. Gastrointest Endosc 2011; 74:347-354
9. Intven M, Reerink O, Philippens ME. Diffusionweighted MRI in locally advanced rectal cancer: pathological response prediction after neo-adjuvant radiochemotherapy. Strahlenther Onkol 2013; 189:117-122
10. Jung SH, Heo SH, Kim JW, et al. Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging. J Magn Reson Imaging 2012; 35:110-116
11. Barbaro B, Vitale R, Valentini V, et al. Diffusionweighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012; 83:594-599
12. Lambregts DM, Vandecaveye V, Barbaro B, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol 2011; 18:2224-2231
13. Kim SH, Lee JM, Hong SH, et al. Locally advanced rectal cancer: added value of diffusionweighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009; 253:116-125
14. DeVries AF, Piringer G, Kremser C, et al. Pretreatment evaluation of microcirculation by dynamic contrast-enhanced magnetic resonance imaging predicts survival in primary rectal cancer patients. Int J Radiat Oncol Biol Phys 2014; 90:1161-1167
15. Lim JS, Kim D, Baek SE, et al. Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. Eur Radiol 2012; 22:1693-1700
16. Oberholzer K, Menig M, Pohlmann A, et al. Rectal cancer: assessment of response to neoadjuvant chemoradiation by dynamic contrast-enhanced MRI. J Magn Reson Imaging 2013; 38:119-126
17. Intven M, Reerink O, Philippens ME. Dynamic contrast enhanced MR imaging for rectal cancer response assessment after neo-adjuvant chemoradiation. J Magn Reson Imaging 2014 Aug 14 [Epub ahead of print]
18. Kim SH, Lee JM, Gupta SN, Han JK, Choi BI. Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. J Magn Reson Imaging 2014; 40:730-737
19. Gollub MJ, Gultekin DH, Akin O, et al. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. Eur Radiol 2012; 22:821-831
20. Ozis SE, Soydal C, Akyol C, et al. The role of 18Ffluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer. World J Surg Oncol 2014; 12:26
21. Maas M, Lambregts DM, Lahaye MJ, et al. Tstaging of rectal cancer: accuracy of 3.0 Tesla MRI compared with 1.5 Tesla. Abdom Imaging 2012; 37:475-481
22. Donmez FY, Tunaci M, Yekeler E, Balik E, Tunaci A, Acunas G. Effect of using endorectal coil in preoperative staging of rectal carcinomas by pelvic MR imaging. Eur J Radiol 2008; 67:139-145
23. Slater A, Halligan S, Taylor SA, Marshall M. Distance between the rectal wall and mesorectal fascia measured by MRI: effect of rectal distension and implications for preoperative prediction of a tumour-free circumferential resection margin. Clin Radiol 2006; 61:65-70
24. Furey E, Jhaveri KS. Magnetic resonance imaging in rectal cancer. Magn Reson Imaging Clin N Am 2014; 22:165-190, v-vi
25. Suzuki C, Torkzad MR, Tanaka S, et al. The importance of rectal cancer MRI protocols on interpretation accuracy. World J Surg Oncol 2008; 6:89
26. Mir N, Sohaib SA, Collins D, Koh DM. Fusion of high b-value diffusion-weighted and T2-weighted MR images improves identification of lymph nodes in the pelvis. J Med Imaging Radiat Oncol 2010; 54:358-364
27. Cong GN, Qin MW, You H, et al. Diffusion weighted imaging combined with magnetic resonance conventional sequences for the diagnosis of rectal cancer [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2009; 31:200-205
28. Alberda WJ, Dassen HP, Dwarkasing RS, et al. Prediction of tumor stage and lymph node involvement with dynamic contrast-enhanced MRI after chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis 2013; 28:573-580
29. Heijnen LA, Lambregts DM, Martens MH, et al. Performance of gadofosveset-enhanced MRI for staging rectal cancer nodes: can the initial promising results be reproduced? Eur Radiol 2014; 24:371-379
30. Rudisch A, Kremser C, Judmaier W, Zunterer H, DeVries AF. Dynamic contrast-enhanced magnetic resonance imaging: a non-invasive method to evaluate significant differences between malignant and normal tissue. Eur J Radiol 2005; 53:514-519
31. Tamakawa M, Kawaai Y, Shirase R, et al. Gadolinium-enhanced dynamic magnetic resonance imaging with endorectal coil for local staging of rectal cancer. Jpn J Radiol 2010; 28:290-298
32. Yao WW, Zhang H, Ding B, et al. Rectal cancer: 3D dynamic contrast-enhanced MRI-correlation with microvascular density and clinicopathological features. Radiol Med (Torino) 2011; 116:366-374
33. Lollert A, Junginger T, Schimanski CC, et al. Rectal cancer: dynamic contrast-enhanced MRI correlates with lymph node status and epidermal growth factor receptor expression. J Magn Reson Imaging 2014; 39:1436-1442
34. Gollub MJ, Cao K, Gultekin DH, et al. Prognostic aspects of DCE-MRI in recurrent rectal cancer. Eur Radiol 2013; 23:3336-3344
35. Hotker AM, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI of rectal cancer in the assessment of response to therapy: a systematic review. Dis Colon Rectum 2014; 57:790-799
36. Szmulowicz UM, Wu JS. Squamous cell carcinoma of the anal canal: a review of the aetiology, presentation, staging, prognosis and methods available for treatment. Sex Health 2012; 9:593-609
37. Hussain SM, Outwater EK, Siegelman ES. Mucinous versus nonmucinous rectal carcinomas: differentiation with MR imaging. Radiology 1999; 213:79-85
38. Younes M, Katikaneni PR, Lechago J. The value of the preoperative mucosal biopsy in the diagnosis of colorectal mucinous adenocarcinoma. Cancer 1993; 72:3588-3592
39. Nasu K, Kuroki Y, Minami M. Diffusion-weighted imaging findings of mucinous carcinoma arising in the ano-rectal region: comparison of apparent diffusion coefficient with that of tubular adenocarcinoma. Jpn J Radiol 2012; 30:120-127
40. Taylor FG, Swift RI, Blomqvist L, Brown G. A systematic approach to the interpretation of preoperative staging MRI for rectal cancer. AJR 2008; 191:1827-1835
41. Brown G, Richards CJ, Newcombe RG, et al. Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology 1999; 211:215-222
42. Taylor FG, Quirke P, Heald RJ, et al. One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. Br J Surg 2011; 98:872-879
43. Edge SB, Byrd DR, Compton CC. AJCC cancer staging handbook: from the AJCC cancer staging manual, 7th ed. New York, NY: Springer, 2010:718
44. Taylor FG, Quirke P, Heald RJ, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253:711-719
45. Gannon CJ, Zager JS, Chang GJ, et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol 2007; 14:1870-1877
46. Engelen SM, Beets-Tan RG, Lahaye MJ, Kessels AG, Beets GL. Location of involved mesorectal and extramesorectal lymph nodes in patients with primary rectal cancer: preoperative assessment with MR imaging. Eur J Surg Oncol 2008; 34:776-781
47. Koh DM, Brown G, Temple L, et al. Distribution of mesorectal lymph nodes in rectal cancer: in vivo MR imaging compared with histopathological examination: initial observations. Eur Radiol 2005; 15:1650-1657
48. Luna-Pérez P, Corral P, Labastida S, Rodr?guez-Coria D, Delgado S. Inguinal lymph node metastases from rectal adenocarcinoma. J Surg Oncol 1999; 70:177-180
49. Kim DJ, Kim JH, Ryu YH, Jeon TJ, Yu JS, Chung JJ. Nodal staging of rectal cancer: high-resolution pelvic MRI versus 18F-FDGPET/CT. J Comput Assist Tomogr 2011; 35:531-534
50. Zhou J, Zhan S, Zhu Q, et al. Prediction of nodal involvement in primary rectal carcinoma without invasion to pelvic structures: accuracy of preoperative CT, MR, and DWIBS assessments relative to histopathologic findings. PLoS ONE 2014; 9:e92779
51. Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003; 227:371-377
52. Heijnen LA, Lambregts DM, Mondal D, et al. Diffusion-weighted MR imaging in primary rectal cancer staging demonstrates but does not characterise lymph nodes. Eur Radiol 2013; 23:3354-3360
53. Cho EY, Kim SH, Yoon JH, et al. Apparent diffusion coefficient for discriminating metastatic from non-metastatic lymph nodes in primary rectal cancer. Eur J Radiol 2013; 82:e662-e668
54. Lahaye MJ, Beets GL, Engelen SM, et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. II. What are the criteria to predict involved lymph nodes? Radiology 2009; 252:81-91
55. Koh DM, George C, Temple L, et al. Diagnostic accuracy of nodal enhancement pattern of rectal cancer at MRI enhanced with ultrasmall superparamagnetic iron oxide: findings in pathologically matched mesorectal lymph nodes. AJR 2010; 194:[web]W505-W513
56. Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging 2015; 41:884-898
57. Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998; 207:529-538
58. Lambregts DM, Heijnen LA, Maas M, et al. Gadofosveset-enhanced MRI for the assessment of rectal cancer lymph nodes: predictive criteria. Abdom Imaging 2013; 38:720-727
59. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206:755-760
60. Kantorová I, Lipská L, B?lohlávek O, Visokai V, Trubaɥ M, Schneiderová M. Routine 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003; 44:1784-1788
61. Tsunoda Y, Ito M, Fujii H, Kuwano H, Saito N. Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT. Jpn J Clin Oncol 2008; 38:347-353
62. Koh DM, Brown G, Husband JE. Nodal staging in rectal cancer. Abdom Imaging 2006; 31:652-659
63. Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 2008; 95:229-236
64. Dresen RC, Peters EE, Rutten HJ, et al. Local recurrence in rectal cancer can be predicted by histopathological factors. Eur J Surg Oncol 2009; 35:1071-1077
65. Yu SK, Tait D, Chau I, Brown G. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy: implications for induction chemotherapy? Int J Radiat Oncol Biol Phys 2013; 87:505-511
66. Bugg WG, Andreou AK, Biswas D, Toms AP, Williams SM. The prognostic significance of MRI-detected extramural venous invasion in rectal carcinoma. Clin Radiol 2014; 69:619-623
67. Chand M, Swift RI, Tekkis PP, Chau I, Brown G. Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. Br J Cancer 2014; 110:19-25
68. Chand M, Bhangu A, Wotherspoon A, et al. EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. Ann Oncol 2014; 25:858-863
69. Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27:5124-5130
70. Park JH, Kim JH, Ahn SD, et al. Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer. Cancer Res Treat 2004; 36:354-359
71. Patel UB, Blomqvist LK, Taylor F, et al. MRI after treatment of locally advanced rectal cancer: how to report tumor response-the MERCURY experience. AJR 2012; 199:[web]W486-W495
72. van der Paardt MP, Zagers MB, Beets-Tan RG, Stoker J, Bipat S. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 2013; 269:101-112
73. Del Vescovo R, Trodella LE, Sansoni I, et al. MR imaging of rectal cancer before and after chemoradiation therapy. Radiol Med (Torino) 2012; 117:1125-1138
74. Grillo-Ruggieri F, Mantello G, Berardi R, et al. Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy. Dis Colon Rectum 2007; 50:1594-1603
75. Lim KS, Tan CH. Diffusion-weighted MRI of adult male pelvic cancers. Clin Radiol 2012; 67:899-908
76. Lambregts DM, Beets GL, Maas M, et al. Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer. Ann Surg 2011; 253:539-545
77. Zhang C, Tong J, Sun X, Liu J, Wang Y, Huang G. 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis. Int J Cancer 2012; 131:2604-2611
78. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR 2000; 174:1005-1008
79. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638-646
80. Jörgren F, Johansson R, Damber L, Lindmark G. Risk factors of rectal cancer local recurrence: population-based survey and validation of the Swedish rectal cancer registry. Colorectal Dis 2010; 12:977-986
81. Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005; 237:123-131
82. Young PE, Womeldorph CM, Johnson EK, et al. Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. J Cancer 2014; 5:262-271
83. Krestin GP, Steinbrich W, Friedmann G. Recurrent rectal cancer: diagnosis with MR imaging versus CT. Radiology 1988; 168:307-311
84. Blomqvist L, Fransson P, Hindmarsh T. The pelvis after surgery and radio-chemotherapy for rectal cancer studied with Gd-DTPA-enhanced fast dynamic MR imaging. Eur Radiol 1998; 8:781-787
85. Glazer HS, Lee JK, Levitt RG, et al. Radiation fibrosis: differentiation from recurrent tumor by MR imaging. Radiology 1985; 156:721-726
86. Kinkel K, Tardivon AA, Soyer P, et al. Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patients. Radiology 1996; 200:453-458
87. Torricelli P, Pecchi A, Luppi G, Romagnoli R. Gadolinium-enhanced MRI with dynamic evaluation in diagnosing the local recurrence of rectal cancer. Abdom Imaging 2003; 28:19-27
88. Zhang C, Chen Y, Xue H, et al. Diagnostic value of FDG-PET in recurrent colorectal carcinoma: a meta-analysis. Int J Cancer 2009; 124:167-173
89. Votrubova J, Belohlavek O, Jaruskova M, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2006; 33:779-784
90. Fiocchi F, Iotti V, Ligabue G, et al. Contrast-enhanced MRI and PET-CT in the evaluation of patients with suspected local recurrence of rectal carcinoma. Radiol Med (Torino) 2010; 115:906-919
91. Pacelli F, Tortorelli AP, Rosa F, et al. Locally recurrent rectal cancer: prognostic factors and longterm outcomes of multimodal therapy. Ann Surg Oncol 2010; 17:152-162
92. Milne T, Solomon MJ, Lee P, et al. Sacral resection with pelvic exenteration for advanced primary and recurrent pelvic cancer: a single-institution experience of 100 sacrectomies. Dis Colon Rectum 2014; 57:1153-1161
93. Chew MH, Brown WE, Masya L, Harrison JD, Myers E, Solomon MJ. Clinical, MRI, and PETCT criteria used by surgeons to determine suitability for pelvic exenteration surgery for recurrent rectal cancers: a Delphi study. Dis Colon Rectum 2013; 56:717-725
94. Radiological Society of North America website. Hussain S, et al. MR rectum cancer. www.radreport.org/template/0000068. Published December 1, 2009. Updated July 16, 2012. Accessed January 2015
95. Cancer Care Ontario website. Al-Sukhni E, Milot L, Fruitman M, et al. Synoptic MRI report for rectal cancer. https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=133271. Accessed November 2014